Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica
Fachbereich
University of Oxford
Oxford, Reino UnidoPublikationen in Zusammenarbeit mit Forschern von University of Oxford (27)
2023
-
Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonists
Communications biology, Vol. 6, Núm. 1, pp. 376
2022
-
Collaboration and knowledge integration for successful brain therapeutics – lessons learned from the pandemic
DMM Disease Models and Mechanisms, Vol. 15, Núm. 12
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
2020
-
Discovery of novel immunopharmacological ligands targeting the IL-17 inflammatory pathway
International Immunopharmacology, Vol. 89
2017
-
Gefitinib and EGFR gene copy number aberrations in esophageal cancer
Journal of Clinical Oncology, Vol. 35, Núm. 20, pp. 2279-2287
-
Solid sorbitan esters nanoparticles are efficient and low-cost vehicles for subunit vaccines: Proof of concept with Neisseria meningitidis protein Mip
Journal of Drug Delivery Science and Technology, Vol. 42, pp. 299-306
2016
-
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356
Autophagy
-
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy, Vol. 12, Núm. 1, pp. 1-222
-
IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer
International Journal of Radiation Oncology Biology Physics, Vol. 95, Núm. 5, pp. 1367-1377
-
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond
PLoS Pathogens, Vol. 12, Núm. 7
2014
-
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): A phase 3, multicentre, double-blind, placebo-controlled randomised trial
The Lancet Oncology, Vol. 15, Núm. 8, pp. 894-904
2009
-
Proteomic analysis of HepaRG cells: A novel cell line that supports hepatitis B virus infection
Journal of Proteome Research, Vol. 8, Núm. 1, pp. 118-122
-
Proteomic analysis of integrin αIIbβ3 outside-in signaling reveals Src-kinase-independent phosphorylation of Dok-1 and Dok-3 leading to SHIP-1 interactions
Journal of Thrombosis and Haemostasis, Vol. 7, Núm. 10, pp. 1718-1726
2008
-
A microtubule interactome: Complexes with roles in cell cycle and mitosis
PLoS Biology, Vol. 6, Núm. 4, pp. 785-795
2007
-
A comprehensive proteomics and genomics analysis reveals novel transmembrane proteins in human platelets and mouse megakaryocytes including G6b-B, a novel immunoreceptor tyrosine-based inhibitory motif protein
Molecular and Cellular Proteomics, Vol. 6, Núm. 3, pp. 548-564
-
Biomarker discovery from uveal melanoma secretomes: Identification of gp100 and cathepsin D in patient serum
Journal of Proteome Research, Vol. 6, Núm. 7, pp. 2802-2811
2006
-
A global proteomics approach identifies novel phosphorylated signaling proteins in GPVI-activated platelets: Involvement of G6f, a novel platelet Grb2-binding membrane adapter
Proteomics, Vol. 6, Núm. 19, pp. 5332-5343
-
Isolation and characterization of cotiaractivase, a novel low molecular weight prothrombin activator from the venom of Bothrops cotiara
Biochimica et Biophysica Acta - Proteins and Proteomics, Vol. 1764, Núm. 5, pp. 863-871
-
Proteome analysis of signaling cascades in human platelets
Blood Cells, Molecules, and Diseases, Vol. 36, Núm. 2, pp. 152-156
-
The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker
International Journal of Cancer, Vol. 119, Núm. 5, pp. 1014-1022